Showing results (311-320 of 1,188) with videos related to
Sort By:
Pageof 119
Pharmaceutical Statistics|June 24, 2022
A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modelingXiao Su, Yisheng Li, Peter Müller, et al.Pharmaceutical Statistics|June 16, 2022
Confirmatory efficacy testing for individual dose-placebo comparisons using serial gatekeeping procedure in dose-finding trials with multiple comparison procedures-modelingYusuke Yamaguchi, Toshifumi Sugitani, Satoshi Yoshida, et al.Pharmaceutical Statistics|June 16, 2022
Weighted log-rank test to compare two survival functions in the presence of dependent censoringPhilippe FlandrePharmaceutical Statistics|December 21, 2022
Statistical considerations for assessing precision of heterogeneous duplicate measurements: An application to pharmaceutical bioanalysisJorge Quiroz, Satrajit RoychoudhuryPharmaceutical Statistics|June 1, 2017
Covariate-adjusted borrowing of historical control data in randomized clinical trialsBaoguang Han, Jia Zhan, Z John Zhong, et al.Pharmaceutical Statistics|June 10, 2017
The time-dependent "cure-death" model investigating two equally important endpoints simultaneously in trials treating high-risk patients with resistant pathogensHarriet Sommer, Martin Wolkewitz, Martin Schumacher, et al.Pharmaceutical Statistics|September 23, 2021
Semi-parametric accelerated failure-time model: A useful alternative to the proportional-hazards model in cancer clinical trialsTomasz BurzykowskiPharmaceutical Statistics|October 4, 2021
Estimands for overall survival in clinical trials with treatment switching in oncologyJuliane Manitz, Natalia Kan-Dobrosky, Hannes Buchner, et al.Pharmaceutical Statistics|July 14, 2022
CUSUMIN: A cumulative sum interval design for cancer phase I dose finding studiesTomoyoshi Hatayama, Seiichi YasuiPharmaceutical Statistics|July 12, 2022
The cross-over of statistical thinking and practices: A pandemic catalystAndrew D GarrettPageof 119